• Citer

CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcomes from OPTIMIZE-1

par Van Laethem, Jean-Luc ;Geboes, K.;Borbath, Ivan;Macarulla Mercade, Teresa;Lambert, Aurélien;Cassier, Philippe Alexandre;Prenen, Hans;Mitry, Emmanuel;Blanc, Jean Frédéric;Pilla, Lorenzo;Feliu, Jaime;Rodriguez Garrote, Mercedes;Pazo-Cid, Roberto Antonio;Gallego, Inmaculada;Smith, Karin Enell;Nordbladh, Karin;Jimenez, David Gomez;Ellmark, Peter;Pico de Coaña, Yago;Ambarkhane, Sumeet Vijay;Beatty, Gregory G.L.;O'Reilly, Eileen Mary
Référence Cell Reports Medicine, 6, 10, 102407
Publication Publié, 2025-10

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcomes from OPTIMIZE-1
Auteur:	Van Laethem, Jean-Luc; Geboes, K.; Borbath, Ivan; Macarulla Mercade, Teresa; Lambert, Aurélien; Cassier, Philippe Alexandre; Prenen, Hans; Mitry, Emmanuel; Blanc, Jean Frédéric; Pilla, Lorenzo; Feliu, Jaime; Rodriguez Garrote, Mercedes; Pazo-Cid, Roberto Antonio; Gallego, Inmaculada; Smith, Karin Enell; Nordbladh, Karin; Jimenez, David Gomez; Ellmark, Peter; Pico de Coaña, Yago; Ambarkhane, Sumeet Vijay; Beatty, Gregory G.L.; O'Reilly, Eileen Mary
Informations sur la publication:	Cell Reports Medicine, 6, 10, 102407
Statut de publication:	Publié, 2025-10
Sujet CREF:	Cancérologie
Mots-clés:	biomarker
	CD40 agonist
	chemotherapy
	classical mPDAC
	ctKRAS
	immunotherapy
	mFOLFIRINOX
	mitazalimab
	mPDAC
	tumor microenvironment
Note générale:	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:2666-3791
	info:doi/10.1016/j.xcrm.2025.102407
	info:pii/S2666-3791(25)00480-X
	info:scp/105019822120
	info:pmid/41061701